Seer Inc. Cl A (SEER) News

Seer Inc. Cl A (SEER): $5.43

-0.03 (-0.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SEER to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter SEER News Items

SEER News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SEER News From Around the Web

Below are the latest news stories about SEER INC that investors may wish to consider to help them evaluate SEER as an investment opportunity.

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference. Seer’s management is scheduled to present and participate in a Q&A session on Tuesday, January 10th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. A live webcast of the session will be available on the Investor s

Yahoo | December 27, 2022

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS

Discovery Life Sciences™ (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research centers. This innovative offering includes both exploratory and targeted proteomics using the Seer Proteograph™ Product Suite, SCIEX LC-MS/MS systems, Olink® Proximity Extension Assay (PEA), and Luminex xMAP® platforms.

Yahoo | December 14, 2022

Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist

Annual award from The Scientist celebrates transformative products like Seer’s Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessibleREDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the Proteograph Product Suite has been named one of The Scientist's 2022 Top 10 Innovations, an annual list that highlights the most transformative and usefu

Yahoo | December 12, 2022

Analysts Just Made A Major Revision To Their Seer, Inc. (NASDAQ:SEER) Revenue Forecasts

One thing we could say about the analysts on Seer, Inc. ( NASDAQ:SEER ) - they aren't optimistic, having just made a...

Yahoo | November 16, 2022

Seer (SEER) Gets a Hold from Morgan Stanley

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Seer (SEER - Research Report), with a price target of $11.00. The company's shares opened today at $7.16.Savant covers the Healthcare sector, focusing on stocks such as Hologic, Illumina, and Thermo Fisher. According to TipRanks, Savant has an average return of -14.9% and a 28.41% success rate on recommended stocks. Seer has an analyst consensus of Hold, with a price target consensus of $10.00, implying a 39.66% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $10.00 price target.

Catie Powers on TipRanks | November 10, 2022

Seer Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Seer ( NASDAQ:SEER ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.96m (up 84% from 3Q 2021). Net...

Yahoo | November 10, 2022

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of 0% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Seer Reports Third Quarter 2022 Financial Results

Proteograph utility is demonstrated as market interest continues to build with multiple studies underwayREDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2022. “During the third quarter, we continued to see growing enthusiasm from our customers across a variety of applications, including discovery, translatio

Yahoo | November 8, 2022

The past year for Seer (NASDAQ:SEER) investors has not been profitable

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

Yahoo | November 2, 2022

Seer to Report Third Quarter 2022 Financial Results on November 8, 2022

REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter of 2022 on Tuesday, November 8, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio.

Yahoo | October 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5116 seconds.